Revenue

The defense contractor signals a strategic shift after lost contracts and procurement delays slash its 2027 revenue outlook, even as profits beat expectations.

A Spanish court has warned Ryanair officials of criminal liability for defying court orders, a major escalation in its bitter feud with the travel platform.

Health Canada grants conditional approval to BioMarin's VOXZOGO, the first drug in the country to target the genetic cause of achondroplasia.

As OneSpaWorld prepares its Q4 results, all eyes are on the wellness giant as a barometer for luxury travel spending and its tech-driven future.

Echodyne is building a $40M facility to meet soaring global demand for advanced radar, aiming to counter drone threats and bolster U.S. manufacturing.

Terex declared a steady dividend, but the real story is its surging stock and a bold forecast, revealing deep confidence in its strategic direction.

NervGen Pharma to unveil data showing its drug NVG-291 provides lasting functional gains for chronic spinal cord injury, a major step forward.

New research proves pocket-sized, AI-powered ultrasound is a game-changer for urgent care, tackling staff shortages and improving patient outcomes.

Consulting firm Sia's new Agent Store moves beyond chatbots, deploying specialized AI agents to automate everything from compliance to crisis management.

Libro seated 11 million guests in 2025, leading a charge against costly reservation platforms with its commission-free, data-centric business model.

Centrus Energy partners with Fluor for a multi-billion-dollar expansion in Ohio, aiming to restore US uranium enrichment and fuel a new era of nuclear power.

Partners Capital closes its largest co-investment fund at over $1B, signaling intense investor appetite for direct private equity deals in the middle market.

A new partnership between QuiX Quantum and Artilux aims to solve quantum computing's biggest hurdles: energy consumption and practical deployment.

With key leadership promotions, AscellaHealth aims to streamline the complex path from drug discovery to patient delivery for life sciences companies worldwide.

A newly identified molecule, HOXD13, both fuels melanoma growth and shields it from the immune system, paving the way for a novel combination therapy.

Cerity Partners is merging with institutional powerhouse Verus, creating a $1.3 trillion advisory firm that will reshape the financial services landscape.

The $10B RIA taps former Hightower CMO Meghan McCartan for a new C-suite role, signaling a major investment in digital strategy to win the advisor race.

A new deal for the rare isotope Actinium-225 could break a major supply bottleneck, accelerating the development of highly targeted cancer treatments.

Forbes Travel Guide unveils its 2026 Star Awards, crowning the first-ever Five-Star cruise ship and expanding the luxury map to new global frontiers.

With its foundational drug a success, Madrigal bets billions on next-gen siRNA tech, aiming to fuse it with Rezdiffra and dominate MASH treatment.